头孢噻肟/舒巴坦复方新药对产酶革兰阴性杆菌体外抑菌效应研究

Bacteriostasis Effect Research of Cefotaxime/Sulbactam Compound Preparation to β-lactmase Production Gram Negative Bacilli in Vitro

目的评价头孢噻肟钠舒巴坦钠复方新药对产不同类型β-内酰胺酶的革兰阴性菌的体外抑菌效应。方法用琼脂平板二倍稀释法测定药物最低抑菌浓度(MIC);PCR及产物测序方法鉴定10种ESBLs的基因。结果头孢噻肟/舒巴坦(CTX/SBT)的MIC50值明显低于头孢噻肟(CTX)或舒巴坦(SBT),而与头孢哌酮/舒巴坦(CPZ/SBT)相当。共检测到四种酶基因,即tem,ctx-m,per-1和oxa-,经部分测序和同源性分析证实为tem-1,ctx-m-1,per-1和oxa-10亚型。但CTX/SBT复方新药在产不同类型β-内酰胺酶(主要是tem和ctx-m)的菌株之间并无明显差异。结论CTX/SBT复方新药对产酶的革兰阴性菌有更好的抗菌活性,对tem和ctx-m型β-内酰胺酶无明显差异。

Objective To evaluate the bacteriostasis effect of cefotaxime/sulbactam compound preparation on β-lactmase production gram negative bacilli in vitro. Methods The minimum inhibitory concentrations （MICs） of different drugs were determined by the agar dilution method;Ten kinds of ESBLs genes were identified by PCR-sequencing. Results The MIC50 of cefotaxime/sulbactam was obviously lower than cefotaxime or sulbactam,but equivalent to cefoperazone/sulbactam. Four β-lactmases genes were detected, viz tem,ctx-m, per-1 and oxa- I . Sequencing and homology analysis confirmed they were tem-l,ctx-m-1 and oxa-10,respectively. But bacteriostasis of cefotaxime/sulbactam had no obviously difference between different β-lactmase subtypes. Conclusion cefotaxime/sulbactam had better antibacterial activity than cefotaxime alone and its bacteriostasis had no obviously difference between different β-lactmase subtypes.